City Therapeutics uses a $200 million IPO to push RNAi beyond liver-limited medicines
City Therapeutics enters the public market with a very specific ambition: make RNA interference therapeutics work in tissues where the first generation of siRNA medicines have struggled to reach. The company priced an upsized initial public offering at $18 a share, raising $200 million after increasing the offering to more than 11.1 million shares from the 9.7 million shares it had initially planned. Shares began trading on Nasdaq under the symbol CTY.
The financing gives the Cambridge, Massachusetts biotech the capital to move several programs forward at once, but the most advanced of them is already aimed at one of the most common problems in cardiovascular medicine: pathologic clotting. City’s lead candidate, CITY-FXI, is being developed for cardiovascular indications and is designed to suppress Factor FXI, a blood protein that contributes to harmful clot formation. In practice, the logic is simple and appealing. If FXI can be dialed down enough to reduce thrombosis without the bleeding burden that limits conventional anticoagulants, the drug could compete in settings where physicians currently rely on agents that are highly effective but often difficult to use safely.
One sentence captures the bet: the company is trying to separate antithrombotic efficacy from bleeding risk.
City’s approach rests on RNAi, a gene-silencing modality that uses small interfering RNA to degrade messenger RNA before the target protein is made. The field is no longer experimental in principle. Alnylam Pharmaceuticals established the therapeutic class in the liver, where four approved RNAi drugs now treat rare diseases driven by hepatic proteins. City’s effort is different in both ambition and engineering. It is building a platform that creates the silencing trigger and designs tissue-targeting ligands meant to deliver the therapy outside the liver, which is where many of the most commercially important diseases reside.
That expansion matters because the liver has long been the easiest organ for RNAi delivery, while the rest of the body has been far less forgiving. Tissue-specific uptake remains the bottleneck, not the biology of gene silencing itself. City’s platform is intended to close that gap.
FXI inhibition, clot prevention, and the search for a cleaner anticoagulant strategy
CITY-FXI uses a ligand that targets low-density lipoprotein receptor-related protein 1, or LRP1, to deliver the siRNA to sites relevant to clot biology. The program is being positioned for several thrombosis settings, including secondary stroke prevention, atrial fibrillation in patients who are not eligible for oral blood thinners, extended secondary prophylaxis after venous thromboembolism, and cancer-associated thrombosis. In each case, current standard care depends on anticoagulants, which work well but can be difficult to sustain in patients with prior bleeding, frailty, procedures, or other contraindications.
Preliminary Phase 1 data from healthy volunteers showed that a single injection produced FXI knockdown of 60% at the lowest dose and 85% at the highest dose. The drug was generally well tolerated. Those early numbers do not answer whether thrombosis will fall in patients or whether bleeding can truly be reduced relative to standard anticoagulants, but they do show biologic activity in the intended direction. In a class that depends on target engagement, that is the first threshold that matters.
The company expects to report more Phase 1 data later this year. A Phase 2 study is also planned in total knee arthroplasty, a setting with a high risk of post-operative blood clots. The design is clinically rational because orthopedic surgery creates a concentrated thrombotic challenge in a relatively predictable window, which makes it a practical proving ground for an antithrombotic RNAi therapy. City plans to begin that study in mid-2027 and report results in early 2028.
Eye disease and anemia programs broaden the commercial case for extrahepatic RNAi
City is not relying on a single cardiovascular asset to justify the platform. Two preclinical programs are moving toward human testing, and each points to a different disease mechanism. CITY-RBP4 is intended for Stargardt disease, a rare inherited vision disorder, with later development also planned in geographic atrophy secondary to macular degeneration. The company expects to begin a Phase 1 trial in healthy volunteers and Stargardt patients later this year, with data expected in early 2028. In eye disease, the appeal of RNAi lies in the potential for durable suppression of disease-driving transcripts within ocular tissue, where local delivery may offer a more controllable pharmacologic footprint than repeated systemic therapy.
The other preclinical program, CITY-TFR2, is aimed at myelofibrosis-associated anemia. It is designed to reduce TFR2 protein, lower hepcidin, and restore iron availability for red blood cell production. City is also exploring the same construct in anemia linked to chronic kidney disease and chronic inflammatory disorders, including inflammatory bowel disease. In those settings, the biological rationale is rooted in iron restriction. Excess hepcidin traps iron where the marrow cannot use it, leaving patients functionally iron-deficient even when total body iron stores may not be absent.
The company plans to start an investigator-initiated study in China and a Phase 1/2 study in myelofibrosis-associated anemia, and it has budgeted about $40 million for that work. Another $20 million is set aside for CITY-RBP4, and about $30 million is earmarked for CITY-FXI’s ongoing Phase 1 development and the start of the knee arthroplasty study. Roughly $70 million is reserved for platform work and preclinical candidates.
City’s pipeline already has outside validation. Bausch + Lomb is collaborating on geographic atrophy programs, while Biogen is partnered with the company in central nervous system disorders. Those alliances do more than add revenue; they signal that the delivery platform may be adaptable enough to reach tissues long considered out of range for RNAi therapeutics. Collaboration revenue totaled $6.3 million in the first half of the year.
The company formed in 2023 and had raised nearly $239 million before going public. Its latest private financing was a $99.5 million Series B round in July. Arch Venture Partners remains the largest shareholder with a 26.7% post-IPO stake. As of the end of September, City’s unaudited cash balance stood at $141.9 million, and the company estimates that the IPO proceeds plus existing cash will support operations into late 2028.
The harder question is not whether RNAi can silence a target. It already can. The question is whether City can turn that molecular precision into repeatable clinical benefit in diseases where delivery, dose, and tissue selectivity have kept many promising programs from becoming medicines. Phase 1 and Phase 2 readouts over the next two years will determine how far this platform can travel beyond the liver.